ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although the ABL kinase inhibitor (imatinib) has proven to be very effective in achieving high remission rates and improving prognosis, up to 33% of CML patients still cannot achieve an optimal response.